KR20230124664A - 세포에서 hla-a를 감소시키기 위한 조성물 및 방법 - Google Patents
세포에서 hla-a를 감소시키기 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20230124664A KR20230124664A KR1020237024853A KR20237024853A KR20230124664A KR 20230124664 A KR20230124664 A KR 20230124664A KR 1020237024853 A KR1020237024853 A KR 1020237024853A KR 20237024853 A KR20237024853 A KR 20237024853A KR 20230124664 A KR20230124664 A KR 20230124664A
- Authority
- KR
- South Korea
- Prior art keywords
- hla
- chr6
- cell
- engineered
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010075704 HLA-A Antigens Proteins 0.000 title claims abstract description 550
- 238000000034 method Methods 0.000 title claims abstract description 165
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 102000011786 HLA-A Antigens Human genes 0.000 title abstract description 525
- 230000014509 gene expression Effects 0.000 claims abstract description 201
- 210000004027 cell Anatomy 0.000 claims description 687
- 108020005004 Guide RNA Proteins 0.000 claims description 390
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 327
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 326
- 125000003729 nucleotide group Chemical group 0.000 claims description 270
- 239000002773 nucleotide Substances 0.000 claims description 259
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 215
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 215
- 238000012239 gene modification Methods 0.000 claims description 148
- 230000005017 genetic modification Effects 0.000 claims description 148
- 235000013617 genetically modified food Nutrition 0.000 claims description 148
- 210000005260 human cell Anatomy 0.000 claims description 145
- 239000011230 binding agent Substances 0.000 claims description 143
- 108700028369 Alleles Proteins 0.000 claims description 142
- 230000004568 DNA-binding Effects 0.000 claims description 128
- 102000039446 nucleic acids Human genes 0.000 claims description 119
- 108020004707 nucleic acids Proteins 0.000 claims description 119
- 150000007523 nucleic acids Chemical class 0.000 claims description 117
- 230000002829 reductive effect Effects 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 230000004048 modification Effects 0.000 claims description 84
- 238000012986 modification Methods 0.000 claims description 84
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 78
- 108091033409 CRISPR Proteins 0.000 claims description 71
- 238000010362 genome editing Methods 0.000 claims description 68
- 102210009886 HLA-C*04:01 Human genes 0.000 claims description 67
- 238000006467 substitution reaction Methods 0.000 claims description 64
- 101150118346 HLA-A gene Proteins 0.000 claims description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 229920001184 polypeptide Polymers 0.000 claims description 53
- 238000000684 flow cytometry Methods 0.000 claims description 52
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 102210009881 HLA-C*07:01 Human genes 0.000 claims description 45
- 108091008874 T cell receptors Proteins 0.000 claims description 45
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 45
- 108020003175 receptors Proteins 0.000 claims description 43
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 42
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 42
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 42
- 108700002010 MHC class II transactivator Proteins 0.000 claims description 41
- 230000008685 targeting Effects 0.000 claims description 37
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 claims description 34
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 claims description 34
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 claims description 34
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 claims description 34
- 102210024051 HLA-B*15:01 Human genes 0.000 claims description 33
- 102210009879 HLA-C*06:02 Human genes 0.000 claims description 33
- 230000000295 complement effect Effects 0.000 claims description 31
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 28
- 230000000735 allogeneic effect Effects 0.000 claims description 27
- 102210042926 HLA-B*44:02 Human genes 0.000 claims description 23
- 102210042928 HLA-C*05:01 Human genes 0.000 claims description 23
- 102220436838 HLA-B*51 Human genes 0.000 claims description 22
- 102210009890 HLA-C*02:02 Human genes 0.000 claims description 22
- 102210024055 HLA-C*03:03 Human genes 0.000 claims description 22
- 102210024054 HLA-C*03:04 Human genes 0.000 claims description 22
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 21
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 claims description 19
- 101710163270 Nuclease Proteins 0.000 claims description 19
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 claims description 17
- 230000004077 genetic alteration Effects 0.000 claims description 17
- 231100000118 genetic alteration Toxicity 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 17
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 15
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 claims description 13
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 13
- 102210009883 HLA-B*07:02 Human genes 0.000 claims description 12
- 102210024050 HLA-B*08:01 Human genes 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 12
- -1 lipid nucleic acid Chemical class 0.000 claims description 12
- 102210009887 HLA-B*13:02 Human genes 0.000 claims description 11
- 102210009888 HLA-B*14:02 Human genes 0.000 claims description 11
- 102210009880 HLA-B*27:05 Human genes 0.000 claims description 11
- 102210009892 HLA-B*52:01 Human genes 0.000 claims description 11
- 108010017588 HLA-B*52:01 antigen Proteins 0.000 claims description 11
- 102210024052 HLA-B*57:01 Human genes 0.000 claims description 11
- 102210009882 HLA-C*07:02 Human genes 0.000 claims description 11
- 102210009885 HLA-C*08:02 Human genes 0.000 claims description 11
- 102210009889 HLA-C*12:02 Human genes 0.000 claims description 11
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 claims description 9
- 241000588650 Neisseria meningitidis Species 0.000 claims description 8
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 241000093740 Acidaminococcus sp. Species 0.000 claims description 7
- 210000004443 dendritic cell Anatomy 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 6
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 6
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 6
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 6
- 241000904817 Lachnospiraceae bacterium Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 210000001178 neural stem cell Anatomy 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 claims description 4
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims description 4
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 4
- 101100194605 Homo sapiens RFXANK gene Proteins 0.000 claims description 4
- 101710190829 Progressive ankylosis protein homolog Proteins 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 102100031366 Ankyrin-1 Human genes 0.000 claims description 3
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 3
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 3
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 claims description 3
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 3
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims description 3
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 3
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 claims description 3
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 claims description 3
- 102100034408 Nuclear transcription factor Y subunit alpha Human genes 0.000 claims description 3
- 101710115878 Nuclear transcription factor Y subunit alpha Proteins 0.000 claims description 3
- 102100022201 Nuclear transcription factor Y subunit beta Human genes 0.000 claims description 3
- 101710205449 Nuclear transcription factor Y subunit beta Proteins 0.000 claims description 3
- 230000026279 RNA modification Effects 0.000 claims description 3
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 102100031719 Nuclear transcription factor Y subunit gamma Human genes 0.000 claims description 2
- 101710150472 Nuclear transcription factor Y subunit gamma Proteins 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 26
- 229940122466 DNA-dependent protein kinase inhibitor Drugs 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 238000009172 cell transfer therapy Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 39
- 102000005962 receptors Human genes 0.000 description 36
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 108091054438 MHC class II family Proteins 0.000 description 25
- 102000043131 MHC class II family Human genes 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 22
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 18
- 102000043129 MHC class I family Human genes 0.000 description 15
- 108091054437 MHC class I family Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 210000000822 natural killer cell Anatomy 0.000 description 14
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 238000011191 terminal modification Methods 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102000040856 WT1 Human genes 0.000 description 10
- 108700020467 WT1 Proteins 0.000 description 10
- 108010041758 cleavase Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000010453 CRISPR/Cas method Methods 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 108700004991 Cas12a Proteins 0.000 description 6
- 108010031325 Cytidine deaminase Proteins 0.000 description 6
- 102100026846 Cytidine deaminase Human genes 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108091008875 B cell receptors Proteins 0.000 description 5
- 101710150423 DNA nickase Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 102210042925 HLA-A*02:01 Human genes 0.000 description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 230000007018 DNA scission Effects 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000009615 deamination Effects 0.000 description 3
- 238000006481 deamination reaction Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 210000005155 neural progenitor cell Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 229940113491 Glycosylase inhibitor Drugs 0.000 description 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000689670 Lachnospiraceae bacterium ND2006 Species 0.000 description 2
- 108091005461 Nucleic proteins Chemical group 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 238000010357 RNA editing Methods 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 101150056237 creB gene Proteins 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 108700015457 human APOBEC3 Proteins 0.000 description 2
- 102000052632 human APOBEC3 Human genes 0.000 description 2
- 102000048646 human APOBEC3A Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- MGAXHFMCFLLMNG-UHFFFAOYSA-N 1h-pyrimidine-6-thione Chemical compound SC1=CC=NC=N1 MGAXHFMCFLLMNG-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 150000005007 4-aminopyrimidines Chemical class 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- ZAOGIVYOCDXEAK-UHFFFAOYSA-N 6-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=NC2=C1NC=N2 ZAOGIVYOCDXEAK-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108010029988 AICDA (activation-induced cytidine deaminase) Proteins 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100040397 C->U-editing enzyme APOBEC-1 Human genes 0.000 description 1
- 102100040399 C->U-editing enzyme APOBEC-2 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000010442 DNA editing Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 101150000578 HLA-B gene Proteins 0.000 description 1
- 101150035071 HLA-C gene Proteins 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 101000964322 Homo sapiens C->U-editing enzyme APOBEC-2 Proteins 0.000 description 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000863978 Homo sapiens Protein downstream neighbor of Son Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101000800426 Homo sapiens Putative C->U-editing enzyme APOBEC-4 Proteins 0.000 description 1
- 101100194594 Homo sapiens RFX5 gene Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 description 1
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 101150065592 NME2 gene Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 102100033091 Putative C->U-editing enzyme APOBEC-4 Human genes 0.000 description 1
- 101150074379 RFX5 gene Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 101150035021 Rfxap gene Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 description 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 210000002378 Th9 Anatomy 0.000 description 1
- 241000039733 Thermoproteus thermophilus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011129 allogeneic cell therapy Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004990 primary immune cell Anatomy 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019527 sweetened beverage Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/15—Non-antibody based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130095P | 2020-12-23 | 2020-12-23 | |
| US63/130,095 | 2020-12-23 | ||
| US202163250996P | 2021-09-30 | 2021-09-30 | |
| US63/250,996 | 2021-09-30 | ||
| US202163254970P | 2021-10-12 | 2021-10-12 | |
| US63/254,970 | 2021-10-12 | ||
| US202163288492P | 2021-12-10 | 2021-12-10 | |
| US63/288,492 | 2021-12-10 | ||
| PCT/US2021/064930 WO2022140586A2 (en) | 2020-12-23 | 2021-12-22 | Compositions and methods for reducing hla-a in a cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230124664A true KR20230124664A (ko) | 2023-08-25 |
Family
ID=81212453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237024853A Pending KR20230124664A (ko) | 2020-12-23 | 2021-12-22 | 세포에서 hla-a를 감소시키기 위한 조성물 및 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024478A1 (https=) |
| EP (1) | EP4267724A2 (https=) |
| JP (1) | JP2024500858A (https=) |
| KR (1) | KR20230124664A (https=) |
| AU (1) | AU2021409732A1 (https=) |
| CA (1) | CA3206284A1 (https=) |
| CL (2) | CL2023001860A1 (https=) |
| CO (1) | CO2023009612A2 (https=) |
| CR (1) | CR20230320A (https=) |
| IL (1) | IL303971A (https=) |
| MX (1) | MX2023007466A (https=) |
| TW (1) | TW202239959A (https=) |
| WO (1) | WO2022140586A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022331424A1 (en) * | 2021-08-16 | 2024-02-22 | Beam Therapeutics Inc. | Persistent allogeneic modified immune cells and methods of use thereof |
| IL320066A (en) * | 2022-10-05 | 2025-06-01 | Garuda Therapeutics Inc | Immunocompatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025038642A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying cd70 |
| IL326191A (en) | 2023-08-14 | 2026-03-01 | Intellia Therapeutics Inc | Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| KR20200138445A (ko) * | 2014-04-24 | 2020-12-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| WO2019160077A1 (ja) * | 2018-02-16 | 2019-08-22 | 国立大学法人京都大学 | 低抗原性細胞の製造方法 |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| AU2019282824C1 (en) | 2018-06-08 | 2026-04-23 | Intellia Therapeutics, Inc. | Modified guide RNAS for gene editing |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| IL282267B2 (en) | 2018-10-15 | 2026-03-01 | Univ Massachusetts | Programmed DNA editing by chimeric deaminase-nme2cas9 proteins |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| WO2020146290A1 (en) * | 2019-01-07 | 2020-07-16 | Crisp-Hr Therapeutics, Inc. | A non-toxic cas9 enzyme and application thereof |
| CA3181340A1 (en) * | 2020-04-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
-
2021
- 2021-12-22 CR CR20230320A patent/CR20230320A/es unknown
- 2021-12-22 MX MX2023007466A patent/MX2023007466A/es unknown
- 2021-12-22 AU AU2021409732A patent/AU2021409732A1/en active Pending
- 2021-12-22 TW TW110148217A patent/TW202239959A/zh unknown
- 2021-12-22 IL IL303971A patent/IL303971A/en unknown
- 2021-12-22 WO PCT/US2021/064930 patent/WO2022140586A2/en not_active Ceased
- 2021-12-22 CA CA3206284A patent/CA3206284A1/en active Pending
- 2021-12-22 KR KR1020237024853A patent/KR20230124664A/ko active Pending
- 2021-12-22 EP EP21856911.9A patent/EP4267724A2/en active Pending
- 2021-12-22 JP JP2023537689A patent/JP2024500858A/ja active Pending
-
2023
- 2023-06-20 CL CL2023001860A patent/CL2023001860A1/es unknown
- 2023-06-22 US US18/339,665 patent/US20240024478A1/en active Pending
- 2023-07-19 CO CONC2023/0009612A patent/CO2023009612A2/es unknown
- 2023-10-17 CL CL2023003086A patent/CL2023003086A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202239959A (zh) | 2022-10-16 |
| WO2022140586A3 (en) | 2022-08-04 |
| EP4267724A2 (en) | 2023-11-01 |
| MX2023007466A (es) | 2023-08-18 |
| CA3206284A1 (en) | 2022-06-30 |
| CR20230320A (es) | 2023-10-23 |
| AU2021409732A9 (en) | 2024-07-18 |
| WO2022140586A2 (en) | 2022-06-30 |
| IL303971A (en) | 2023-08-01 |
| CL2023001860A1 (es) | 2024-02-09 |
| JP2024500858A (ja) | 2024-01-10 |
| US20240024478A1 (en) | 2024-01-25 |
| AU2021409732A1 (en) | 2023-07-20 |
| CL2023003086A1 (es) | 2024-05-03 |
| CO2023009612A2 (es) | 2023-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230124664A (ko) | 세포에서 hla-a를 감소시키기 위한 조성물 및 방법 | |
| KR20230135068A (ko) | 세포에서 ciita를 유전적으로 변형시키기 위한 조성물및 방법 | |
| US20240016934A1 (en) | Compositions and Methods for Reducing MHC Class II in a Cell | |
| US20250262302A1 (en) | Compositions and Methods for Reducing MHC Class I in a Cell | |
| CN116745406A (zh) | 用于减少细胞中hla-a的组合物和方法 | |
| HK40099255A (zh) | 用於减少细胞中hla-a的组合物和方法 | |
| KR20250037791A (ko) | 게놈 편집을 위한 조성물 및 방법 | |
| CN116783285A (zh) | 用于细胞中基因修饰ciita的组合物和方法 | |
| CN116802274A (zh) | 用于减少细胞中ii类mhc的组合物和方法 | |
| HK40126949A (zh) | 用於减少细胞中的mhc i类的组合物和方法 | |
| HK40094124A (zh) | 用於细胞中基因修饰ciita的组合物和方法 | |
| WO2025038642A1 (en) | Compositions and methods for genetically modifying cd70 | |
| CN119384498A (zh) | 用于对细胞进行遗传修饰的方法和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230720 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241220 Comment text: Request for Examination of Application |